VISION acuity.

The recent VISION trial showed that Lu-177-PSMA-617 improved survival when added to standard treatment of men with PSMA-positive mCRPC that progresses after androgen receptor pathway inhibitor and taxane chemotherapy. What factors predict response to Lu-177-PSMA-617? Here are three nomograms that predict overall survival, survival free from PSA progression, and chance of achieving at least 50% decline in PSA using clinicopathologic and PSMA-PET factors, complete with an online calculator to add to your favorites bar. | Gafita, Lancet Oncol 2021